Product Description
The company's proprietary platform technology is what makes it innovative and unique. It's "Cell BioEngineMAP" is a cutting-edge platform for developing cell therapy assets, leveraging the remarkable potential of universal umbilical cord-derived blood stem cells. These cells serve as a foundational source, which we expand, differentiate, and de-differentiate to produce powerful cells at large scale for clinical applications. Complementing this, our "Cell BioEngineAI" platform employs artificial intelligence to predict donor availability and target characteristics, ensuring the safety and efficacy of HLA-compatible therapies. Our goal is to create a ready-to-use, 'off-the-shelf' cell bank with therapeutic products that cover over 85% of the population, available at selected blood centers. (Sourced from: https://www.linkedin.com/company/cell-bioengines/)
Mechanisms of Action: Cell Therapy,NK
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cell BioEngines
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Multiple Myeloma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|